| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Epoprostenol | 22 | 2021 | 75 | 5.970 |
Why?
|
| Dinoprostone | 12 | 2023 | 208 | 5.090 |
Why?
|
| Intramolecular Oxidoreductases | 19 | 2021 | 81 | 4.420 |
Why?
|
| Cytochrome P-450 Enzyme System | 18 | 2021 | 200 | 3.730 |
Why?
|
| Cyclooxygenase 1 | 12 | 2021 | 67 | 3.650 |
Why?
|
| Receptors, Thromboxane A2, Prostaglandin H2 | 10 | 2010 | 12 | 2.560 |
Why?
|
| Arachidonic Acid | 12 | 2016 | 118 | 2.560 |
Why?
|
| Cyclooxygenase 2 | 10 | 2023 | 483 | 2.230 |
Why?
|
| Protein Engineering | 8 | 2021 | 100 | 2.060 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 6 | 2023 | 521 | 1.830 |
Why?
|
| Anti-Inflammatory Agents | 3 | 2023 | 461 | 1.620 |
Why?
|
| Prostaglandin H2 | 7 | 2019 | 10 | 1.590 |
Why?
|
| Thromboxane A2 | 6 | 2023 | 21 | 1.510 |
Why?
|
| Prostaglandin-E Synthases | 6 | 2023 | 28 | 1.460 |
Why?
|
| Thromboxane-A Synthase | 7 | 2019 | 22 | 1.440 |
Why?
|
| Receptors, Prostaglandin | 5 | 2018 | 29 | 1.360 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 3 | 2022 | 200 | 1.290 |
Why?
|
| Models, Molecular | 17 | 2008 | 1732 | 1.150 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 7 | 2021 | 215 | 1.100 |
Why?
|
| Antioxidants | 2 | 2021 | 507 | 1.090 |
Why?
|
| Receptors, Epoprostenol | 7 | 2007 | 10 | 1.060 |
Why?
|
| Recombinant Fusion Proteins | 6 | 2019 | 1555 | 1.040 |
Why?
|
| Thromboxanes | 2 | 2023 | 12 | 1.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 10 | 2017 | 624 | 1.010 |
Why?
|
| Alprostadil | 2 | 2017 | 33 | 0.970 |
Why?
|
| Megakaryocytes | 1 | 2023 | 104 | 0.910 |
Why?
|
| Neurodegenerative Diseases | 2 | 2016 | 264 | 0.900 |
Why?
|
| Drug Discovery | 3 | 2018 | 324 | 0.870 |
Why?
|
| Benzene Derivatives | 1 | 2021 | 23 | 0.800 |
Why?
|
| Cannabidiol | 1 | 2021 | 42 | 0.790 |
Why?
|
| Ligands | 11 | 2018 | 995 | 0.780 |
Why?
|
| Thrombosis | 2 | 2021 | 781 | 0.770 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 8 | 2008 | 71 | 0.750 |
Why?
|
| Receptors, Prostaglandin E | 2 | 2011 | 14 | 0.730 |
Why?
|
| Up-Regulation | 2 | 2020 | 2450 | 0.700 |
Why?
|
| Recombinant Proteins | 12 | 2021 | 2927 | 0.690 |
Why?
|
| Receptors, Prostaglandin E, EP3 Subtype | 2 | 2017 | 11 | 0.680 |
Why?
|
| Protein Conformation | 12 | 2010 | 1258 | 0.660 |
Why?
|
| HEK293 Cells | 6 | 2021 | 1489 | 0.650 |
Why?
|
| Drugs, Chinese Herbal | 2 | 2011 | 48 | 0.650 |
Why?
|
| Fibrinolytic Agents | 1 | 2021 | 324 | 0.650 |
Why?
|
| Disease Resistance | 1 | 2018 | 23 | 0.640 |
Why?
|
| Binding Sites | 14 | 2017 | 2171 | 0.640 |
Why?
|
| Molecular Mimicry | 2 | 2008 | 72 | 0.630 |
Why?
|
| Protein Binding | 14 | 2018 | 3438 | 0.630 |
Why?
|
| Neuroprotective Agents | 1 | 2020 | 215 | 0.620 |
Why?
|
| Intracellular Membranes | 5 | 2006 | 108 | 0.620 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gs | 3 | 2006 | 43 | 0.610 |
Why?
|
| Prostaglandins | 4 | 2018 | 77 | 0.600 |
Why?
|
| Amino Acid Sequence | 18 | 2008 | 4233 | 0.590 |
Why?
|
| COS Cells | 9 | 2010 | 377 | 0.590 |
Why?
|
| Stroke | 2 | 2018 | 1144 | 0.590 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2021 | 852 | 0.580 |
Why?
|
| Endoplasmic Reticulum | 6 | 2016 | 308 | 0.570 |
Why?
|
| Oxyquinoline | 1 | 2016 | 6 | 0.570 |
Why?
|
| Models, Chemical | 2 | 2007 | 186 | 0.560 |
Why?
|
| Amino Acids | 1 | 2019 | 728 | 0.560 |
Why?
|
| Endoplasmic Reticulum, Smooth | 1 | 2015 | 2 | 0.540 |
Why?
|
| Molecular Sequence Data | 18 | 2008 | 6089 | 0.530 |
Why?
|
| Organometallic Compounds | 1 | 2016 | 191 | 0.520 |
Why?
|
| Microsomes | 4 | 2022 | 61 | 0.520 |
Why?
|
| Mutagenesis, Site-Directed | 7 | 2017 | 611 | 0.520 |
Why?
|
| Oxidative Stress | 2 | 2021 | 1129 | 0.480 |
Why?
|
| Protein Structure, Tertiary | 7 | 2005 | 1487 | 0.470 |
Why?
|
| Hippocampus | 1 | 2020 | 915 | 0.470 |
Why?
|
| Protein Structure, Secondary | 7 | 2015 | 336 | 0.460 |
Why?
|
| Receptors, Thromboxane | 2 | 2003 | 7 | 0.460 |
Why?
|
| Animals | 35 | 2021 | 59536 | 0.460 |
Why?
|
| Peptide Fragments | 6 | 2015 | 1271 | 0.460 |
Why?
|
| Genetic Therapy | 5 | 2013 | 1616 | 0.450 |
Why?
|
| Insulin | 1 | 2019 | 1454 | 0.450 |
Why?
|
| Cell Line | 10 | 2020 | 5114 | 0.450 |
Why?
|
| Iloprost | 2 | 2020 | 8 | 0.420 |
Why?
|
| Crystallography, X-Ray | 4 | 2017 | 627 | 0.380 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2010 | 52 | 0.370 |
Why?
|
| Hypertension, Pulmonary | 3 | 2013 | 462 | 0.370 |
Why?
|
| Diabetes Mellitus | 1 | 2019 | 1054 | 0.370 |
Why?
|
| Cells, Cultured | 4 | 2011 | 5637 | 0.360 |
Why?
|
| Platelet Aggregation | 5 | 2019 | 257 | 0.350 |
Why?
|
| Humans | 50 | 2023 | 261506 | 0.350 |
Why?
|
| Antihypertensive Agents | 2 | 2010 | 395 | 0.350 |
Why?
|
| Catalysis | 3 | 2021 | 250 | 0.340 |
Why?
|
| Solutions | 5 | 2008 | 104 | 0.340 |
Why?
|
| Adipocytes | 1 | 2011 | 305 | 0.340 |
Why?
|
| Mutagenesis | 2 | 2007 | 483 | 0.340 |
Why?
|
| Neurons | 1 | 2020 | 2287 | 0.340 |
Why?
|
| Myocardial Infarction | 2 | 2018 | 1374 | 0.340 |
Why?
|
| Heart Diseases | 2 | 2013 | 732 | 0.330 |
Why?
|
| Heart Arrest | 1 | 2013 | 358 | 0.320 |
Why?
|
| Vasodilator Agents | 1 | 2010 | 219 | 0.320 |
Why?
|
| Mice, Transgenic | 4 | 2020 | 4143 | 0.310 |
Why?
|
| Receptors, G-Protein-Coupled | 2 | 2009 | 488 | 0.310 |
Why?
|
| Embryonic Stem Cells | 1 | 2010 | 301 | 0.310 |
Why?
|
| Regeneration | 1 | 2010 | 279 | 0.300 |
Why?
|
| DNA, Complementary | 4 | 2017 | 869 | 0.300 |
Why?
|
| 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid | 4 | 2010 | 37 | 0.290 |
Why?
|
| Peptides | 6 | 2015 | 1479 | 0.290 |
Why?
|
| Stem Cell Transplantation | 2 | 2013 | 1360 | 0.290 |
Why?
|
| Prunella | 1 | 2006 | 2 | 0.280 |
Why?
|
| Prostaglandin Endoperoxides, Synthetic | 1 | 2005 | 4 | 0.280 |
Why?
|
| Models, Biological | 1 | 2015 | 3254 | 0.280 |
Why?
|
| Disease Models, Animal | 3 | 2018 | 7222 | 0.270 |
Why?
|
| Kinetics | 6 | 2009 | 2049 | 0.270 |
Why?
|
| Pulmonary Artery | 1 | 2010 | 499 | 0.270 |
Why?
|
| Biomimetic Materials | 1 | 2005 | 41 | 0.270 |
Why?
|
| Down-Regulation | 1 | 2011 | 2074 | 0.260 |
Why?
|
| Signal Transduction | 5 | 2017 | 11965 | 0.260 |
Why?
|
| Endometrium | 2 | 2006 | 470 | 0.260 |
Why?
|
| Calcium Signaling | 3 | 2017 | 284 | 0.260 |
Why?
|
| Substrate Specificity | 4 | 2007 | 549 | 0.250 |
Why?
|
| Blood Pressure | 2 | 2013 | 1467 | 0.250 |
Why?
|
| Catalytic Domain | 3 | 2016 | 303 | 0.240 |
Why?
|
| Heart | 1 | 2010 | 1223 | 0.230 |
Why?
|
| Delayed-Action Preparations | 1 | 2023 | 208 | 0.230 |
Why?
|
| Spectrometry, Fluorescence | 3 | 2010 | 209 | 0.230 |
Why?
|
| Receptors, Cholinergic | 3 | 1992 | 84 | 0.220 |
Why?
|
| GTP-Binding Proteins | 1 | 2023 | 321 | 0.210 |
Why?
|
| Maze Learning | 2 | 2020 | 132 | 0.200 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2021 | 84 | 0.200 |
Why?
|
| Cannabis | 1 | 2021 | 65 | 0.190 |
Why?
|
| Penis | 2 | 2013 | 123 | 0.190 |
Why?
|
| Transfection | 5 | 2013 | 2944 | 0.180 |
Why?
|
| Muscle, Smooth, Vascular | 3 | 2013 | 330 | 0.180 |
Why?
|
| Blood Platelets | 2 | 2023 | 731 | 0.180 |
Why?
|
| Mice | 10 | 2020 | 34495 | 0.180 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 2010 | 568 | 0.180 |
Why?
|
| Celecoxib | 1 | 2019 | 200 | 0.170 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2021 | 503 | 0.170 |
Why?
|
| Hemostatics | 1 | 2019 | 88 | 0.170 |
Why?
|
| Erectile Dysfunction | 2 | 2013 | 212 | 0.170 |
Why?
|
| Spodoptera | 2 | 2008 | 63 | 0.170 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2010 | 548 | 0.170 |
Why?
|
| Baculoviridae | 2 | 2008 | 86 | 0.170 |
Why?
|
| Epithelial Cells | 1 | 2006 | 1818 | 0.160 |
Why?
|
| Sequence Alignment | 3 | 2005 | 844 | 0.160 |
Why?
|
| Myocytes, Smooth Muscle | 2 | 2012 | 198 | 0.160 |
Why?
|
| Models, Animal | 1 | 2021 | 664 | 0.160 |
Why?
|
| Sequence Homology, Amino Acid | 3 | 2005 | 997 | 0.160 |
Why?
|
| Tryptophan | 2 | 2009 | 127 | 0.160 |
Why?
|
| NFATC Transcription Factors | 1 | 2018 | 96 | 0.160 |
Why?
|
| Microscopy, Fluorescence | 2 | 2011 | 769 | 0.160 |
Why?
|
| Brain Diseases | 1 | 2021 | 403 | 0.160 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2018 | 146 | 0.150 |
Why?
|
| MicroRNAs | 1 | 2011 | 2947 | 0.150 |
Why?
|
| Circular Dichroism | 2 | 2009 | 113 | 0.150 |
Why?
|
| Peptides, Cyclic | 2 | 2003 | 139 | 0.140 |
Why?
|
| Drug Design | 3 | 2008 | 375 | 0.140 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 2017 | 123 | 0.140 |
Why?
|
| Cloning, Molecular | 2 | 2008 | 1213 | 0.140 |
Why?
|
| Colon | 1 | 2019 | 670 | 0.140 |
Why?
|
| Conserved Sequence | 2 | 2008 | 469 | 0.130 |
Why?
|
| Neoplasms | 2 | 2021 | 15193 | 0.130 |
Why?
|
| Protein Domains | 1 | 2017 | 314 | 0.130 |
Why?
|
| Genetic Vectors | 3 | 2013 | 1694 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2018 | 507 | 0.130 |
Why?
|
| Hemorrhage | 1 | 2019 | 712 | 0.130 |
Why?
|
| Molecular Weight | 1 | 2015 | 629 | 0.120 |
Why?
|
| Ophiopogon | 1 | 2014 | 1 | 0.120 |
Why?
|
| Prostaglandins I | 1 | 2013 | 2 | 0.120 |
Why?
|
| Stem Cells | 2 | 2012 | 1213 | 0.120 |
Why?
|
| Monocrotaline | 1 | 2013 | 3 | 0.120 |
Why?
|
| Hypertrophy, Right Ventricular | 1 | 2013 | 14 | 0.120 |
Why?
|
| Disulfides | 2 | 2004 | 116 | 0.120 |
Why?
|
| In Vitro Techniques | 2 | 2008 | 1618 | 0.110 |
Why?
|
| Cell Survival | 1 | 2020 | 3045 | 0.110 |
Why?
|
| Inflammation | 2 | 2016 | 2522 | 0.110 |
Why?
|
| Fatty Acids, Unsaturated | 2 | 2003 | 94 | 0.110 |
Why?
|
| Penile Erection | 1 | 2013 | 86 | 0.110 |
Why?
|
| Protein Transport | 1 | 2015 | 734 | 0.110 |
Why?
|
| Cattle | 2 | 2005 | 783 | 0.110 |
Why?
|
| Oligopeptides | 1 | 2015 | 429 | 0.110 |
Why?
|
| Polysaccharides | 1 | 2014 | 197 | 0.110 |
Why?
|
| Cell Engineering | 1 | 2012 | 37 | 0.110 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2014 | 224 | 0.100 |
Why?
|
| Arginine | 2 | 2006 | 500 | 0.100 |
Why?
|
| Erabutoxins | 1 | 1991 | 3 | 0.100 |
Why?
|
| Cobra Neurotoxin Proteins | 1 | 1991 | 6 | 0.100 |
Why?
|
| Calcium | 2 | 2011 | 1537 | 0.100 |
Why?
|
| Computer Simulation | 2 | 2007 | 1529 | 0.100 |
Why?
|
| Hydrazines | 2 | 2003 | 208 | 0.100 |
Why?
|
| Reactive Oxygen Species | 1 | 2016 | 987 | 0.100 |
Why?
|
| Acetylcholine | 1 | 1991 | 96 | 0.100 |
Why?
|
| Bungarotoxins | 1 | 1990 | 17 | 0.100 |
Why?
|
| Feeder Cells | 1 | 2010 | 13 | 0.090 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2011 | 202 | 0.090 |
Why?
|
| Feces | 1 | 2014 | 770 | 0.090 |
Why?
|
| Memory | 1 | 2013 | 429 | 0.090 |
Why?
|
| Growth Inhibitors | 1 | 2010 | 149 | 0.090 |
Why?
|
| Gene Expression | 2 | 2008 | 3570 | 0.090 |
Why?
|
| Base Sequence | 4 | 2006 | 4917 | 0.090 |
Why?
|
| Behavior, Animal | 1 | 2013 | 709 | 0.090 |
Why?
|
| Biocatalysis | 1 | 2009 | 63 | 0.090 |
Why?
|
| Point Mutation | 2 | 2011 | 769 | 0.090 |
Why?
|
| 6-Ketoprostaglandin F1 alpha | 1 | 2008 | 10 | 0.090 |
Why?
|
| Thromboxane B2 | 1 | 2008 | 27 | 0.090 |
Why?
|
| Mitochondria | 1 | 2016 | 1282 | 0.080 |
Why?
|
| Radioligand Assay | 1 | 2008 | 54 | 0.080 |
Why?
|
| Phospholipids | 1 | 2009 | 177 | 0.080 |
Why?
|
| Titrimetry | 1 | 2007 | 10 | 0.080 |
Why?
|
| Crystallography | 1 | 2007 | 57 | 0.080 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2009 | 585 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 4938 | 0.080 |
Why?
|
| Structure-Activity Relationship | 3 | 2006 | 931 | 0.080 |
Why?
|
| Endothelium, Vascular | 1 | 2012 | 891 | 0.080 |
Why?
|
| Molecular Conformation | 1 | 2007 | 171 | 0.080 |
Why?
|
| Solubility | 1 | 2007 | 242 | 0.080 |
Why?
|
| Immunoenzyme Techniques | 1 | 2009 | 1165 | 0.080 |
Why?
|
| Endothelial Cells | 1 | 2013 | 1048 | 0.070 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 2 | 2003 | 923 | 0.070 |
Why?
|
| Liposomes | 1 | 2009 | 684 | 0.070 |
Why?
|
| Rats, Inbred F344 | 2 | 2019 | 224 | 0.070 |
Why?
|
| Biomarkers | 2 | 2019 | 5047 | 0.070 |
Why?
|
| Apoptosis | 4 | 2018 | 7591 | 0.070 |
Why?
|
| Mutation | 3 | 2017 | 15179 | 0.070 |
Why?
|
| Plant Structures | 1 | 2006 | 8 | 0.070 |
Why?
|
| Anxiety | 1 | 2013 | 1179 | 0.070 |
Why?
|
| Peroxisome Proliferator-Activated Receptors | 1 | 2006 | 25 | 0.070 |
Why?
|
| Templates, Genetic | 1 | 2005 | 86 | 0.070 |
Why?
|
| DNA Primers | 2 | 2006 | 1399 | 0.070 |
Why?
|
| Anti-Obesity Agents | 1 | 2006 | 30 | 0.070 |
Why?
|
| Drug Delivery Systems | 1 | 2010 | 669 | 0.070 |
Why?
|
| Phenylalanine | 1 | 2006 | 142 | 0.070 |
Why?
|
| Sequence Analysis, Protein | 1 | 2005 | 81 | 0.070 |
Why?
|
| Alanine | 1 | 2006 | 240 | 0.070 |
Why?
|
| Protons | 1 | 2007 | 473 | 0.060 |
Why?
|
| Interleukin-1 | 1 | 2006 | 461 | 0.060 |
Why?
|
| Blotting, Western | 1 | 2010 | 3536 | 0.060 |
Why?
|
| Colorectal Neoplasms | 1 | 2019 | 3578 | 0.060 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2008 | 803 | 0.060 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2018 | 3552 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2011 | 2054 | 0.060 |
Why?
|
| Electron Spin Resonance Spectroscopy | 1 | 2003 | 62 | 0.060 |
Why?
|
| Rhodopsin | 1 | 2003 | 70 | 0.060 |
Why?
|
| Vasoconstrictor Agents | 1 | 2004 | 151 | 0.060 |
Why?
|
| Antibody Specificity | 2 | 2002 | 334 | 0.060 |
Why?
|
| Gastrointestinal Tract | 1 | 2006 | 324 | 0.050 |
Why?
|
| Oxidation-Reduction | 1 | 2004 | 717 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 8873 | 0.050 |
Why?
|
| Binding Sites, Antibody | 1 | 2002 | 135 | 0.050 |
Why?
|
| Amino Acid Substitution | 1 | 2004 | 644 | 0.050 |
Why?
|
| Neoplasm Transplantation | 2 | 2018 | 1519 | 0.050 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2002 | 189 | 0.050 |
Why?
|
| Coronary Vessels | 1 | 2006 | 665 | 0.050 |
Why?
|
| Cell Membrane | 1 | 2005 | 850 | 0.050 |
Why?
|
| Myasthenia Gravis | 2 | 1992 | 99 | 0.050 |
Why?
|
| Pancreatic Neoplasms | 1 | 2018 | 5061 | 0.050 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2004 | 444 | 0.050 |
Why?
|
| DNA | 2 | 2003 | 2693 | 0.050 |
Why?
|
| Enzyme Inhibitors | 2 | 2006 | 1879 | 0.050 |
Why?
|
| Cell Proliferation | 2 | 2018 | 7226 | 0.040 |
Why?
|
| Rats | 3 | 2013 | 6086 | 0.040 |
Why?
|
| Cell Differentiation | 1 | 2010 | 4078 | 0.040 |
Why?
|
| Calcineurin | 1 | 2018 | 128 | 0.040 |
Why?
|
| Mice, Nude | 2 | 2018 | 4307 | 0.040 |
Why?
|
| Male | 6 | 2020 | 123000 | 0.040 |
Why?
|
| Cardiovascular Diseases | 1 | 2010 | 2195 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2019 | 32848 | 0.040 |
Why?
|
| Sulfonamides | 1 | 2006 | 1823 | 0.040 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2018 | 566 | 0.040 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 1996 | 177 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2018 | 14289 | 0.030 |
Why?
|
| Succinic Acid | 1 | 2014 | 23 | 0.030 |
Why?
|
| Fermentation | 1 | 2014 | 60 | 0.030 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2014 | 95 | 0.030 |
Why?
|
| Sequence Homology, Nucleic Acid | 2 | 1992 | 354 | 0.030 |
Why?
|
| Time Factors | 1 | 2008 | 12926 | 0.030 |
Why?
|
| Isoenzymes | 1 | 1996 | 614 | 0.030 |
Why?
|
| Prebiotics | 1 | 2014 | 34 | 0.030 |
Why?
|
| Familial Primary Pulmonary Hypertension | 1 | 2013 | 21 | 0.030 |
Why?
|
| Nerve Crush | 1 | 2013 | 9 | 0.030 |
Why?
|
| Intestinal Mucosa | 1 | 2019 | 1081 | 0.030 |
Why?
|
| Epitopes | 2 | 1992 | 685 | 0.030 |
Why?
|
| Deoxycytidine | 1 | 2018 | 1353 | 0.030 |
Why?
|
| 4-Aminopyridine | 1 | 2012 | 41 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2018 | 2216 | 0.030 |
Why?
|
| Purines | 1 | 2014 | 273 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2011 | 10331 | 0.030 |
Why?
|
| Half-Life | 1 | 2012 | 259 | 0.030 |
Why?
|
| Autoantibodies | 2 | 1992 | 576 | 0.030 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2013 | 265 | 0.030 |
Why?
|
| Fear | 1 | 2013 | 254 | 0.030 |
Why?
|
| Culture Media, Conditioned | 1 | 2012 | 260 | 0.030 |
Why?
|
| Plant Extracts | 1 | 2014 | 215 | 0.030 |
Why?
|
| Cell Growth Processes | 1 | 2012 | 342 | 0.030 |
Why?
|
| Electric Stimulation | 1 | 2013 | 426 | 0.030 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2013 | 292 | 0.030 |
Why?
|
| Torpedo | 1 | 1991 | 36 | 0.020 |
Why?
|
| Potassium Channels | 1 | 2012 | 162 | 0.020 |
Why?
|
| Female | 5 | 2018 | 141928 | 0.020 |
Why?
|
| Receptors, Nicotinic | 1 | 1992 | 190 | 0.020 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2011 | 367 | 0.020 |
Why?
|
| Tissue Engineering | 1 | 2013 | 269 | 0.020 |
Why?
|
| Computer Graphics | 1 | 1990 | 82 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2013 | 1382 | 0.020 |
Why?
|
| Metabolomics | 1 | 2014 | 478 | 0.020 |
Why?
|
| Neovascularization, Physiologic | 1 | 2012 | 345 | 0.020 |
Why?
|
| Actins | 1 | 2013 | 608 | 0.020 |
Why?
|
| Hypoxia | 1 | 2012 | 443 | 0.020 |
Why?
|
| Intestines | 1 | 2014 | 686 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2011 | 1082 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2013 | 2063 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2011 | 1643 | 0.020 |
Why?
|
| Microbiota | 1 | 2014 | 547 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2013 | 1459 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 2014 | 6942 | 0.020 |
Why?
|
| Prostatectomy | 1 | 2009 | 962 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2009 | 2292 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2018 | 14551 | 0.010 |
Why?
|
| Software | 1 | 1990 | 1321 | 0.010 |
Why?
|
| Molecular Structure | 1 | 2004 | 515 | 0.010 |
Why?
|
| Diabetic Retinopathy | 1 | 2006 | 178 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2012 | 2819 | 0.010 |
Why?
|
| Phenotype | 1 | 2012 | 6295 | 0.010 |
Why?
|
| Survival Rate | 1 | 2013 | 12221 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 1 | 2006 | 1547 | 0.010 |
Why?
|
| Atherosclerosis | 1 | 2006 | 935 | 0.010 |
Why?
|
| Valine | 1 | 1996 | 176 | 0.010 |
Why?
|
| Rabbits | 1 | 1996 | 957 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2009 | 5542 | 0.010 |
Why?
|
| Pyridostigmine Bromide | 1 | 1992 | 15 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 1992 | 191 | 0.010 |
Why?
|
| Leukemia, Monocytic, Acute | 1 | 1992 | 31 | 0.010 |
Why?
|
| Leukemia, Erythroblastic, Acute | 1 | 1992 | 118 | 0.010 |
Why?
|
| Antibody Formation | 1 | 1992 | 383 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1992 | 682 | 0.010 |
Why?
|
| Prednisone | 1 | 1992 | 984 | 0.010 |
Why?
|
| T-Lymphocytes | 2 | 1992 | 3869 | 0.010 |
Why?
|
| Polyethylene Glycols | 1 | 1992 | 615 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 1992 | 1688 | 0.000 |
Why?
|
| Polymerase Chain Reaction | 1 | 1992 | 3203 | 0.000 |
Why?
|
| Cyclophosphamide | 1 | 1992 | 3001 | 0.000 |
Why?
|
| RNA, Messenger | 1 | 1992 | 6150 | 0.000 |
Why?
|
| Adolescent | 1 | 1992 | 31252 | 0.000 |
Why?
|
| Aged | 1 | 1992 | 70117 | 0.000 |
Why?
|
| Adult | 1 | 1992 | 77950 | 0.000 |
Why?
|
| Middle Aged | 1 | 1992 | 86204 | 0.000 |
Why?
|